Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$4.99
+5.1%		$4.61
$2.78
▼
$6.45
$399.34M0.3428,540 shs245,333 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$13.34
+0.9%		$13.07
$6.45
▼
$17.15
$387.93M0.98196,244 shs220,702 shs
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
$13.31
+2.0%		$13.73
$5.78
▼
$19.40
$352.98M0.93738,674 shs1.19 million shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.00
$0.09
▼
$0.16
$95.35M1.034.72 million shs790,936 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
+1.06%+2.81%-2.46%-14.26%+34.94%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-0.75%+6.18%-8.89%-12.39%+78.41%
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-5.57%-11.94%-19.74%+12.02%+111.51%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$4.99
+5.1%		$4.61
$2.78
▼
$6.45
$399.34M0.3428,540 shs245,333 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$13.34
+0.9%		$13.07
$6.45
▼
$17.15
$387.93M0.98196,244 shs220,702 shs
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
$13.31
+2.0%		$13.73
$5.78
▼
$19.40
$352.98M0.93738,674 shs1.19 million shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.00
$0.09
▼
$0.16
$95.35M1.034.72 million shs790,936 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
+1.06%+2.81%-2.46%-14.26%+34.94%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-0.75%+6.18%-8.89%-12.39%+78.41%
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-5.57%-11.94%-19.74%+12.02%+111.51%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.50
Moderate BuyN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.75
Moderate Buy$20.2952.55% Upside
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
2.89
Moderate Buy$37.67184.13% Upside
Zomedica Corp. stock logo
ZOM
Zomedica
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZOM, TENX, ENTA, and AVIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
7/29/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$35.00
7/28/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$35.00
7/22/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$39.00
7/17/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/2/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$27.00
6/30/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$35.00
6/23/2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
6/22/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$34.00 ➝ $40.00
(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$3.53 per shareN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$65.32M5.92N/AN/A$3.03 per share4.39
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
N/AN/AN/AN/A$4.28 per shareN/A
Zomedica Corp. stock logo
ZOM
Zomedica
$25.19M0.00N/AN/A$0.24 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$158.35M-$2.11N/AN/AN/AN/A-57.01%-51.49%8/6/2026 (Estimated)
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-$52.60M-$1.48N/AN/AN/AN/A-61.54%-57.42%8/12/2026 (Estimated)
Zomedica Corp. stock logo
ZOM
Zomedica
-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/A

Latest ZOM, TENX, ENTA, and AVIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-$0.38N/AN/AN/AN/AN/A
8/10/2026Q3 2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$0.5095N/AN/AN/A$16.76 millionN/A
8/6/2026Q2 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.5550N/AN/AN/A$33.03 millionN/A
7/31/2026Q2 2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-$0.3813-$0.35+$0.0313-$0.35N/AN/A
5/12/2026Q1 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.60-$0.57+$0.03-$0.57$22.42 millionN/A
5/12/2026Q1 2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-$0.40-$0.35+$0.05-$0.35N/AN/A
5/11/2026Q2 2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
7.89
7.89
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
3.84
3.84
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
N/A
15.07
14.52
Zomedica Corp. stock logo
ZOM
Zomedica
N/A
10.82
10.15

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
1.67%
Zomedica Corp. stock logo
ZOM
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
21.60%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
11.48%
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
10.81%
Zomedica Corp. stock logo
ZOM
Zomedica
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7080.03 million62.74 millionOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16029.08 million25.74 millionOptionable
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
926.52 million23.66 millionNot Optionable
Zomedica Corp. stock logo
ZOM
Zomedica
50979.95 million938.89 millionNot Optionable

Recent News About These Companies

ZOMEDICA CORP
July 30, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-aktien/zomedica-corp.htm
Zomedica Corp. (ZOMDF) Discusses Sales Strategy and Execution in Veterinary Medicine Transcript
July 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4925486-zomedica-corp-zomdf-discusses-sales-strategy-and-execution-in-veterinary-medicine-transcript
Zomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the Clinic
July 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69032582-zomedica-corp-zomedica-announces-fourth-friday-at-four-webinar-on-july-24-2026-zomedica-s-sales-organization-from-strategy-to-the-clinic-200.htm
Zomedica Corp. (ZOMDF) Discusses Five Pillars Framework for Clinical Value and Shareholder Returns in Veterinary Practice Transcript
June 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918178-zomedica-corp-zomdf-discusses-five-pillars-framework-for-clinical-value-and-shareholder
Zomedica Corp. (ZOMDF) Q1 2026 Earnings Call Transcript
May 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4910179-zomedica-corp-zomdf-q1-2026-earnings-call-transcript
Zomedica Pharmaceuticals (ZOMDF) SEC Filings
May 23, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/zomdf/sec-filings
Zomedica Corp.: Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech Market
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68495283-zomedica-corp-zomedica-announces-fifth-friday-at-four-webinar-on-may-29th-first-quarter-2026-financial-results-and-a-deep-dive-into-the-companion-200.htm
Zomedica Corp.: Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
May 6, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68417346-zomedica-corp-zomedica-announces-record-first-quarter-revenue-of-dollar-8-8-million-reflecting-35-annual-growth-and-dollar-47-5-million-in-liquidity-200.htm
Zomedica Corp. (ZOMDF) Discusses Manufacturing Strategy and Quality Operations for Veterinary Diagnostics and Therapeutics Transcript
April 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4894185-zomedica-corp-zomdf-discusses-manufacturing-strategy-and-quality-operations-for-veterinary
Zomedica Insider Trading Activity | OTC:ZOMDF | Benzinga
April 7, 2026  |  benzinga.comhttps://www.benzinga.com/quote/ZOMDF/insider-trades
Zomedica Corp. (ZOMDF) Discusses the Equine Veterinary Market Opportunity Transcript
March 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4886748-zomedica-corp-zomdf-discusses-the-equine-veterinary-market-opportunity-transcript
Zomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA Platform
March 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67982896-zomedica-corp-zomedica-announces-strategic-collaboration-with-boehringer-ingelheim-to-expand-equine-endocrine-diagnostic-testing-using-truforma-plat-200.htm
Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and ...
March 16, 2026  |  pharmiweb.comP
Zomedica Corp.: Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor Webinar
March 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67900211-zomedica-corp-zomedica-to-review-2025-financial-results-and-highlight-equine-market-opportunity-during-march-27th-fourth-friday-at-four-investor-w-200.htm
Zomedica Corp. (ZOMDF) Discusses R&D Strategy and Innovation in Veterinary Diagnostic and Therapeutic Technologies Transcript
February 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4876632-zomedica-corp-zomdf-discusses-r-and-d-strategy-and-innovation-in-veterinary-diagnostic-and
Zomedica Corp.: Zomedica Expands Distribution of TRUVIEW Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary Pathology
February 25, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67786974-zomedica-corp-zomedica-expands-distribution-of-truview-digital-microscopy-platform-through-national-agreement-with-moichor-a-leader-in-veterinary-p-200.htm
Zomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation Pipeline
February 5, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67623822-zomedica-corp-zomedica-announces-fourth-friday-at-four-webinar-on-february-27th-focused-on-research-development-and-its-innovation-pipeline-200.htm
Zomedica Corp. (ZOMDF) Discusses Technology and Digital Innovation Driving Growth in Animal Health Transcript
January 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4862372-zomedica-corp-zomdf-discusses-technology-and-digital-innovation-driving-growth-in-animal
Zomedica Corp.: Zomedica Expands its TRUVIEW Microscopy Platform with AI Diagnostic Interpretation, Growing its Market Opportunity
January 23, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67515330-zomedica-corp-zomedica-expands-its-truview-microscopy-platform-with-ai-diagnostic-interpretation-growing-its-market-opportunity-200.htm
Zomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven Growth
January 14, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67431831-zomedica-corp-zomedica-announces-fourth-friday-at-four-webinar-on-january-23rd-focused-on-digital-innovation-technology-driven-growth-200.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Rocket Lab Electron rocket on coastal launch pad with company logo overlay, symbolizing space tech integration strategy.
Rocket Lab’s Stock Drop Comes With a Bullish Twist
By Ryan Hasson | July 10, 2026
Illuminated AV logo displayed on a riveted metal panel surrounded by cables and machinery components.
AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
By Jeffrey Neal Johnson | July 10, 2026
Person using a mouse at a desk while viewing a candlestick death cross stock price chart with moving averages on a computer monitor.
Buyer Beware: These 2 Stocks Charts Just Displayed a Death Cross
By Jessica Mitacek | July 10, 2026
PayPal logo displayed on a curved reception desk in a modern office lobby with city skyline views.
PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid
By Jeffrey Neal Johnson | July 16, 2026
Digital display showing a stock price chart alongside a table of values, changes, and percent changes with up and down arrows.
3 Small-Cap Stocks Trading Under $10 With Room to Run
By Bridget Bennett | July 15, 2026
Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$4.99 +0.24 (+5.05%)
Closing price 04:00 PM Eastern
Extended Trading
$4.88 -0.12 (-2.30%)
As of 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$13.34 +0.12 (+0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$13.32 -0.02 (-0.11%)
As of 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Tenax Therapeutics stock logo

Tenax Therapeutics NASDAQ:TENX

$13.31 +0.26 (+1.99%)
Closing price 04:00 PM Eastern
Extended Trading
$13.27 -0.04 (-0.30%)
As of 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Zomedica stock logo

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas